SHENYANG, China, Sept. 7 /PRNewswire-Asia/ -- 3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products today announced its planned participation in the following investor conferences:
Sep 9-10, 2010 Susquehanna Fourth Annual Beijing Management Summit
Beijing
Sep 13-14, 2010 Morgan Stanley Global Healthcare Conference
NYC
Oct 20-22, 2010 Citigroup Greater China Investor Conference
Macau
Nov 1-2, 2010 Goldman Sachs China Investment Frontier Conference
Beijing
Nov 3-5, 2010 Bank of America Merrill Lynch China Investment Summit
Beijing
Nov 9-11, 2010 Morgan Stanley Asia Pacific Summit 2010
Singapore
Please see http://bbs.3sbio.com/en/News/xShowInfo_nnn6.aspx?ID=65 for further updates.
About 3SBio Inc.
3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 500 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see http://www.3SBio.com for more information.
For more information, please contact:
Investor Contacts
Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: +86-24-2581-1820
Email: ir@3SBio.com
Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: +852-8191-6991
Email: ir@3SBio.com
